Teva Pharmaceutical Industries Limited (TEVA)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$39.66+0.33%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $46.3B
- P/E (trailing)
- 66.1
- Forward P/E
- 12.9
- 52-week range
- $18.83 – $40.79
- 52-week change
- +96.96%
- EPS (trailing)
- $0.60
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $17.3B (+4.32%)
- Net income
- $1.4B
- Operating margin
- 12.5%
- Diluted EPS
- $1.21
- Free cash flow
- $1.1B
From the company’s annual report on SEC EDGAR.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
Headquarters: Tel Aviv-Yafo, Israel · 31,173 employees · tevapharm.com